No Clinically Significant Drug Interactions Between Teldy and Co-Amoxiclav or Fluconazole
Teldy (tenofovir disoproxil fumarate/lamivudine/dolutegravir) can be safely co-administered with both Co-amoxiclav (amoxicillin/clavulanic acid) and oral fluconazole without dose adjustments or significant safety concerns.
Drug Interaction Analysis
Dolutegravir and Fluconazole
The available evidence demonstrates no drug interactions between dolutegravir and fluconazole 1. Dolutegravir is not metabolized by CYP3A4, CYP2C9, or CYP2C19—the primary enzymes that fluconazole inhibits 2. While fluconazole is a moderate CYP3A4 inhibitor and strong CYP2C19 inhibitor, dolutegravir's metabolism occurs through UGT1A1-mediated glucuronidation, making it unaffected by fluconazole's enzyme inhibition profile.
Tenofovir/Lamivudine and Fluconazole
No interactions exist between tenofovir disoproxil fumarate or lamivudine and fluconazole 1, 3. These nucleoside reverse transcriptase inhibitors (NRTIs) are eliminated primarily through renal excretion and do not undergo significant hepatic metabolism via the cytochrome P450 system that fluconazole affects.
Co-Amoxiclav Interactions
Co-amoxiclav (amoxicillin/clavulanic acid) has no documented interactions with any component of Teldy. Beta-lactam antibiotics like amoxicillin are not metabolized through cytochrome P450 pathways and do not interact with antiretroviral medications through pharmacokinetic mechanisms.
Clinical Recommendations
- Continue all three medications concurrently without dose modifications
- No additional monitoring is required beyond standard HIV prophylaxis follow-up
- No timing adjustments needed for medication administration—all can be taken together or separately as convenient
Important Caveats
While fluconazole can cause QT prolongation 2, this is primarily a concern with high-dose fluconazole (≥800 mg) or in patients with pre-existing cardiac risk factors (hypokalemia, structural heart disease, concurrent QT-prolonging medications). For typical fluconazole dosing (150-400 mg), this risk is minimal and does not contraindicate use with Teldy.
The enzyme-inhibiting effects of fluconazole persist 4-5 days after discontinuation due to its long half-life 2, but this is irrelevant for Teldy components given the absence of metabolic interactions.